Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

Brage, E. Terán; Ruíz, Jonnathan Roldán; Martín, Javier González; Rodríguez, Juan Diego Oviedo; Tocino, R. Vidal; Diego, S Rodriguez; Hernández, Pedro Luis Sánchez; Hernandez, Lorena; Sánchez, Emilio

doi:10.1016/j.cpccr.2022.100153

Cited by 10 publications

(12 citation statements)

References 16 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different COVID-19 vaccine side effects studies have shown findings that are similar to ours [ 23 , 24 ]. A randomized controlled trial (RCT) that enrolled 43,000 volunteers with a median age of 52 years provided the first data to assess the effectiveness of the Pfizer COVID-19 vaccine.…”

Section: Discussionsupporting

confidence: 88%

“…The mean of vaccination side effects experienced in general well-being on a scale of 1 to 10 was 4.31 for all participants, with the highest in the Modena vaccine and the lowest in the mixed vaccine. Several studies found a similar pattern, with the majority of adverse effects being mild to moderate in severity and typically going away a few days after vaccination [ 24 , 30 ].…”

Section: Discussionmentioning

confidence: 81%

“…Several studies have linked the administration of Pfizer or AstraZeneca vaccines to fatigue [23,24,29,30]. In addition, gastrointestinal symptoms, mainly nausea, were recorded by 23% of those who had taken the AstraZeneca vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…Although vaccine reactogenicity appears to decline with aging and is correlated with a transient rise in inflammatory cytokines, it is not thought to be a reliable predictor of a favorable immune response [ 28 ]. Several studies have linked the administration of Pfizer or AstraZeneca vaccines to fatigue [ 23 , 24 , 29 , 30 ]. In addition, gastrointestinal symptoms, mainly nausea, were recorded by 23% of those who had taken the AstraZeneca vaccine.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Intricacies Affiliated With Post-COVID Vaccine Complications in Makkah Province, Saudi Arabia

Sheriff¹,

Basalib²,

Mereani³

et al. 2022

Cureus

View full text Add to dashboard Cite

IntroductionCOVID-19 vaccine side effects have a fundamental role in public confidence in the vaccine and its uptake process. Thus far, evidence on vaccine safety has been exclusively obtained from manufacturer-sponsored studies; therefore, this study is designed to assess post-COVID-19 vaccine complications in Makkah province, Saudi Arabia. MethodA cross-sectional study included 840 subjects conducted from August to November 2022 to collect data about COVID-19 vaccine side effects. A validated questionnaire was used with 21 multiple-choice items covering demographic data, COVID-19 vaccination type, side effects, and medication used to relieve side effects. The online Raosoft sample size calculator (Raosoft Inc., Seattle, Washington) was utilized for sample size calculation. The Statistical Package for the Social Sciences version 22.0 (IBM Inc., Armonk, New York) was utilized to carry out descriptive statistics. The Shapiro-Wilk test was used to evaluate normal data distribution. Significance of categorized data made by the Pearson's Chi-Squared test and of the vaccination side effects experienced in general wellbeing on a scale of 1-10 by the Kruskal-Wallis test. ResultThe survey found that most participants in the 18-26 age group were from Jeddah, women, and Saudis. Only 7.1% of participants had comorbidities alone, and 63.1% of participants had previously had COVID-19. The vaccine types used in this study were primarily Pfizer (83.3%), AstraZeneca (9.5%), Moderna (3.6%), and combination vaccines (3.6%). The majority of the participants received vaccination up to the third dose. No side effects were reported by 9.5% of participants, while mild and severe side effects were reported by 90.5% and 23.8% of participants, respectively. Mild side effects included injection site pain, redness, tenderness, or itching (34.5%), fatigue (22.6%), low-grade fever, chills, diarrhea, headache (17.9%), and myalgia (14.3%). ConclusionThe majority of the side effects of COVID-19 vaccination were minor reactions (90.5%), but 23.8% were found to be serious side effects, most of which lasted one to three days. More independent studies are needed to investigate gender differences, COVID-19 vaccine efficacy, and the prevalence of side effects in other populations conducted by academic institutions. Additional independent research on vaccine safety is urgently needed to increase public confidence in vaccines and to better understand risk factors for vaccine side effects.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Intricacies Affiliated With Post-COVID Vaccine Complications in Makkah Province, Saudi Arabia

Sheriff¹,

Basalib²,

Mereani³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Another case report by Brage et al described a 62-year-old woman diagnosed with stage four lung adenocarcinoma affecting both lungs and lymph nodes who was treated with osimertinib [ 24 ]. She presented with fever and hypotension and showed tachycardia and skin pallor.…”

Section: Reviewmentioning

confidence: 99%

COVID-19 Vaccination-Associated Myocarditis: A Literature Review

Mannan¹,

Kashyap²,

Akram³

et al. 2022

Cureus

View full text Add to dashboard Cite

Myocarditis is defined as a non-ischemic inflammation of the middle layer of the heart. It ensues changes that can lead to acute heart failure, dilated cardiomyopathy, and sudden death. Myocarditis is caused by several infectious and non-infectious agents. Vaccines are also known to cause myocarditis. The use of the coronavirus disease (COVID-19) vaccination was started to combat the severity of the COVID-19 infection and reduce the mortality and morbidity associated with it. The vaccination, however, caused side effects like myocarditis, among others. In order to investigate the association between the COVID-19 vaccination and myocarditis in adults and adolescents, we conducted a literature review by searching three databases: Google Scholar, PubMed, and ScienceDirect. From the published literature, we found that, though it is rare, the various vaccinations available can cause symptoms of myocarditis as a side effect more commonly in patients who have received both doses of a particular vaccine and that there are significant changes in cardiac magnetic resonance imaging (CMRI) and other biochemical markers, with young males being more commonly affected. Further prospective trial-based studies are required to establish a concrete relationship between myocarditis and the COVID-19 vaccine.

show abstract

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors

et al. 2022

View full text Add to dashboard Cite

Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post‐vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA‐1237 vaccine, and were compared with a group of 26 non‐cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS‐CoV‐2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non‐cancer groups were significant in individuals without previous SARS‐CoV‐2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non‐cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS‐CoV‐2 vaccination programs.

show abstract

Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

Cited by 10 publications

References 16 publications

Intricacies Affiliated With Post-COVID Vaccine Complications in Makkah Province, Saudi Arabia

Intricacies Affiliated With Post-COVID Vaccine Complications in Makkah Province, Saudi Arabia

COVID-19 Vaccination-Associated Myocarditis: A Literature Review

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors

Contact Info

Product

Resources

About